Considerable evidence links urokinase plasminogen activator (uPA) bound to its surface receptor (uPAR) with enhanced invasiveness of cancer cells. By blocking uPAR expression in human epidermoid carcinoma cells (HEp3), we have now identified an additional and novel in vivo function for this receptor by showing that receptor-deficient cells enter a state of dormancy reminiscent of that observed in human cancer metastasis. Its main characteristic is survival without signs of progressive growth. Five clones transfected with a vector expressing uPAR antisense RNA under the β-actin promoter were isolated and shown to have uPAR (at the mRNA and protein levels) reduced by 50 to 80%; four clones, transfected with vector alone and having uPAR levels similar to those of parental cells, served as controls. In confirmation of our previous results, reduced uPAR always coincided with a significantly reduced invasiveness. Each of the control clones produced rapidly growing, highly metastatic tumors within 2 wk of inoculation on chorioallantoic membranes (CAMs) of chick embryos. In contrast, each of the clones with low surface uPAR, whose proliferation rate in culture was indistinguishable from controls, remained dormant for up to 5 mo when inoculated on CAMs. Thus, the reduction in uPAR altered the phenotype of HEp3 tumor cells from tumorigenic to dormant. Although protracted, tumor dormancy was not permanent since in spite of maintaining low uPAR levels, each of the in vivo–passaged antisense clones eventually reemerged from dormancy to initiate progressive growth and to form metastases at a level of 20 to 90% of that of fully malignant control. This observation suggested that other factors, whose expression is dependent on cumulative and prolonged in vivo effects, can compensate for the lack of a full complement of surface uPAR required for the expression of malignant properties. These “reemerged,” uPAR-deficient clones were easily distinguishable from the vector-transfected controls by the fact that after only 1 wk in culture, the invasion of CAM by all five clones and tumorigenicity of four of the five clones were reduced back to the values observed before in vivo maintenance. In contrast, dissociated and in vitro–grown cells of control tumors were fully invasive and produced large, metastatic tumors when reinoculated on CAMs. Quantitation of the percent of apoptotic and S-phase cells in vivo, in the control and uPAR-deficient, dormant clones, showed that the mechanism responsible for the dormancy was a diminished proliferation.
Skip Nav Destination
Article navigation
5 May 1997
Article|
May 05 1997
Reduction in Surface Urokinase Receptor Forces Malignant Cells into a Protracted State of Dormancy
W. Yu,
W. Yu
The Rochelle Belfer Chemotherapy Foundation Laboratory, Department of Medicine, Division of Neoplastic Diseases, Mount Sinai School of Medicine, New York 10029
Search for other works by this author on:
J. Kim,
J. Kim
The Rochelle Belfer Chemotherapy Foundation Laboratory, Department of Medicine, Division of Neoplastic Diseases, Mount Sinai School of Medicine, New York 10029
Search for other works by this author on:
L. Ossowski
L. Ossowski
The Rochelle Belfer Chemotherapy Foundation Laboratory, Department of Medicine, Division of Neoplastic Diseases, Mount Sinai School of Medicine, New York 10029
Search for other works by this author on:
W. Yu
The Rochelle Belfer Chemotherapy Foundation Laboratory, Department of Medicine, Division of Neoplastic Diseases, Mount Sinai School of Medicine, New York 10029
J. Kim
The Rochelle Belfer Chemotherapy Foundation Laboratory, Department of Medicine, Division of Neoplastic Diseases, Mount Sinai School of Medicine, New York 10029
L. Ossowski
The Rochelle Belfer Chemotherapy Foundation Laboratory, Department of Medicine, Division of Neoplastic Diseases, Mount Sinai School of Medicine, New York 10029
1. Abbreviations used in this paper: CAM, chorioallantoic membrane; HEp3, human epidermoid carcinoma; IUdR and BUdR, iododeoxyuridine and bromodexoyuridine; uPA, urokinase plasminogen activator; uPAR, uPA receptor.
Address all correspondence to L. Ossowski, The Rochelle Belfer Chemotherapy Foundation Laboratory, Department of Medicine, Division of Neoplastic Diseases, Box 1178, Mount Sinai School of Medicine, New York, NY 10029. Tel.: (212) 241-3194. Fax: (212) 996-5787.
Received:
August 05 1996
Revision Received:
February 19 1997
Online ISSN: 1540-8140
Print ISSN: 0021-9525
1997
J Cell Biol (1997) 137 (3): 767–777.
Article history
Received:
August 05 1996
Revision Received:
February 19 1997
Citation
W. Yu, J. Kim, L. Ossowski; Reduction in Surface Urokinase Receptor Forces Malignant Cells into a Protracted State of Dormancy. J Cell Biol 5 May 1997; 137 (3): 767–777. doi: https://doi.org/10.1083/jcb.137.3.767
Download citation file:
Sign in
Don't already have an account? Register
Client Account
You could not be signed in. Please check your email address / username and password and try again.
Could not validate captcha. Please try again.
Sign in via your Institution
Sign in via your InstitutionSuggested Content
Email alerts
Advertisement
Advertisement